The global respiratory syncytial virus attachment glycoprotein market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Respiratory syncytial virus or RSV is a common respiratory virus. It usually causes mild, cold-like symptoms and most people recover in a week or two, however, it is very serious especially for infants and older adults. The major factor accelerating the growth of the market is the increasing prevalence of respiratory syncytial virus (RSV) attachment glycoprotein across the globe. According to the National Institute of Allergy and Infectious Disease (NIH), almost all children become infected with RSV by age 2. Additionally, an estimated 75,000 to 125,000 of them are hospitalized each year. Furthermore, it affects an estimated 64 million people with a mortality rate of 160,000 each year. Hence, the rising incidence of the disease is driving the growth of the global respiratory syncytial virus attachment glycoproteins market during the forecast period.

Some major players operating in the market include Bavarian Nordic A/S, Sanofi S.A., and F. Hoffmann-La Roche Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2021, Sanofi announced Nirsevimab being developed in partnership with AstraZeneca. It is the first investigational extended half-life monoclonal antibody (mAb) that aims to protect all infants who enter the first RSV season when they are at the highest risk for severe RSV disease.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Bavarian Nordic A/S, Sanofi S.A., and F. Hoffmann-La Roche Ltd., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Respiratory Syncytial Virus Attachment Glycoprotein Market Report by Segment

By Type 

    • VIS-RSV

    • TRL-3D3

    • AX-14

    • MVA-RSV

    • Others

By Application 

    • Clinics

    • Hospitals

    • Others

Global Respiratory Syncytial Virus Attachment Glycoprotein Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa